Pharmacokinetic considerations regarding non-viral cancer gene therapy

Cancer Science

Volumn 99, Issue 5, 2008, Pages 856-862

  Nishikawa, Makiya ^a   Takakura, Yoshinobu ^a   Hashida, Mitsuru ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERFERON; LIPOSOME; MACROGOL; NAKED DNA; PLASMID DNA; PLASMID VECTOR; POLYETHYLENEIMINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

AREA UNDER THE CURVE; CANCER GENE THERAPY; COLON ADENOCARCINOMA; COMPLEX FORMATION; CONTROLLED RELEASE FORMULATION; ELECTROPORATION; HUMAN; HYDRODYNAMICS BASED TRANSFECTION; IN VIVO GENE TRANSFER; MEAN RESIDENCE TIME; METASTASIS; METASTASIS INHIBITION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TISSUE DISTRIBUTION; TRANSGENE; ULTRASOUND; BIOLOGICAL MODEL; GENE THERAPY; GENE VECTOR; METABOLISM; NEOPLASM;

GENE THERAPY; GENETIC VECTORS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; TRANSGENES;

EID: 43649106064     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00774.x     Document Type: Review

References (80)

1. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999; 286: 2244-5.
2. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-66.
3. Sakurai H, Sakurai F, Kawabata K et al. Comparison of gene expression efficiency and innate immune response induced by Ad vector and lipoplex. J Control Release 2007; 117: 430-7.
4. Kobayashi N, Nishikawa M, Takakura Y. The hydrodynamics-based procedure for controlling the pharmacokinetics of gene medicines at whole body, organ and cellular levels. Adv Drug Deliv Rev 2005; 57: 713-31.
5. Yasuda K, Ogawa Y, Yamane I, Nishikawa M, Takakura Y. Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and.-.independent pathways. J Leukoc Biol 2005; 77: 71-9.
6. Kako K, Nishikawa M, Yoshida H, Takakura Y. Effects of inflammatory response on in.vivo transgene expression by plasmid DNA in mice. J Pharm Sci 2008; in press.
7. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
8. Yasuda K, Wagner H, Takakura Y. Role of immunostimulatory DNA and TLR9 in gene therapy. Crit Rev Ther Drug Carrier Syst 2006; 23: 89-110.
9. Takaoka A, Wang Z, Choi MK et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007; 448: 501-5.
10. Nishikawa M, Huang L. Nonviral vectors in the new millennium: Delivery barriers in gene transfer. Hum Gene Ther 2001; 12: 861-70.
11. Nishikawa M, Hashida M. Nonviral approaches satisfying various requirements for effective in.vivo gene therapy. Biol Pharm Bull 2002; 25: 275-83.
12. Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer Sci 2006; 97: 689-96.
13. Kobayashi N, Kuramoto T, Chen S, Watanabe Y, Takakura Y. Therapeutic effect of intravenous interferon gene delivery with naked plasmid DNA in murine metastasis models. Mol Ther 2002; 6: 737-44.
14. Kawano H, Nishikawa M, Mitsui M et al. Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid DNA. Int J Cancer 2007; 121: 401-6.
15. Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-8.
16. Hickman MA, Malone RW, Lehmann-Bruinsma K et al. Gene expression following direct injection of DNA into liver. Hum Gene Ther 1994; 5: 1477-83.
17. Thanaketpaisarn O, Nishikawa M, Yamashita F, Hashida M. Tissue-specific characteristics of in.vivo electric gene transfer by tissue and intravenous injection of plasmid DNA. Pharm Res 2005; 22: 883-91.
18. Schwartz B, Benoist C, Abdallah B et al. Gene transfer by naked DNA into adult mouse brain. Gene Ther 1996; 3: 405-11.
19. Soubrane C, Mouawad R, Rixe O et al. Direct gene transfer of a plasmid carrying the herpes simplex virus-thymidine kinase gene (HSV-TK) in transplanted murine melanoma: In.vivo study. Eur J Cancer 1996; 32A: 691-5.
20. Nomura T, Nakajima S, Kawabata K, Yamashita F, Takakura Y, Hashida M. Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res 1997; 57: 2681-6.
21. Nomura T, Yasuda K, Yamada T et al. Gene expression and antitumor effects following direct interferon (IFN)-γ gene transfer with naked plasmid DNA and DC-chol liposome complexes in mice. Gene Ther 1999; 6: 121-9.
22. Natsume A, Mizuno M, Ryuke Y, Yoshida J. Antitumor effect and cellular immunity activation by murine interferon-β gene transfer against intracerebral glioma in mouse. Gene Ther 1999; 6: 1626-33.
23. O'Hara AJ, Howell JM, Taplin RH et al. The spread of transgene expression at the site of gene construct injection. Muscle Nerve 2001; 24: 488-95.
24. Somiari S, Glasspool-Malone J, Drabick JJ et al. Theory and in vivo application of electroporative gene delivery. Mol Ther 2000; 2: 178-87.
25. Rols MP, Delteil C, Golzio M, Dumond P, Cros S, Teissie J. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 1998; 16: 168-71.
26. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16: 867-70.
27. Sakai M, Nishikawa M, Thanaketpaisarn O, Yamashita F, Hashida M. Hepatocyte-targeted gene transfer by combination of vascularly delivered plasmid DNA and in vivo electroporation. Gene Ther 2005; 12: 607-16.
28. Bommannan D, Menon GK, Okuyama H, Elias PM, Guy RH. Sonophoresis. II. Examination of the mechanism(s) of ultrasound-enhanced transdermal drug delivery. Pharm Res 1992; 9: 1043-7.
29. Huber PE, Pfisterer P. In vitro and in.vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound. Gene Ther 2000; 7: 1516-25.
30. Taniyama Y, Tachibana K, Hiraoka K et al. Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 2002; 105: 1233-9.
31. Suzuki R, Takizawa T, Negishi Y et al. Gene delivery by combination of novel liposomal bubbles with perfluoropropane and ultrasound. J Control Release 2007; 117: 130-6.
32. Liu F, Huang L. Noninvasive gene delivery to the liver by mechanical massage. Hepatology 2002; 35: 1314-19.
33. Liu F, Lei J, Vollmer R, Huang L. Mechanism of liver gene transfer by mechanical massage. Mol Ther 2004; 9: 452-7.
34. Kawabata K, Takakura Y, Hashida M. The fate of plasmid DNA after intravenous injection in mice: Involvement of scavenger receptors in its hepatic uptake. Pharm Res 1995; 12: 825-30.
35. Budker V, Zhang G, Knechtle S, Wolff JA. Naked DNA delivered intraportally expresses efficiently in hepatocytes. Gene Ther 1996; 3: 593-8.
36. Song YK, Liu F, Liu D. Enhanced gene expression in mouse lung by prolonging the retention time of intravenously injected plasmid DNA. Gene Ther 1998; 5: 1531-7.
37. Liu F, Huang L. Improving plasmid DNA-mediated liver gene transfer by prolonging its retention in the hepatic vasculature. J Gene Med 2001; 3: 569-76.
38. Liu F, Nishikawa M, Clemens PR, Huang L. Transfer of full-length Dmd to the diaphragm muscle of Dmd mdx/mdx mice through systemic administration of plasmid DNA. Mol Ther 2001; 4: 45-51.
39. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-7.
40. Kobayashi N, Hirata K, Chen S, Kawase A, Nishikawa M, Takakura Y. Hepatic delivery of particulates in the submicron range by a hydrodynamics-based procedure: Implications for particulate gene delivery systems. J Gene Med 2004; 6: 455-63.
41. Kobayashi N, Nishikawa M, Hirata K, Takakura Y. Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: Implication of a nonspecific process in efficient intracellular gene delivery. J Gene Med 2004; 6: 584-92.
42. Zhang G, Gao X, Song YK et al. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 2004; 11: 675-82.
43. Suda T, Gao X, Stolz DB, Liu D. Structural impact of hydrodynamic injection on mouse liver. Gene Ther 2007; 14: 129-37.
44. Felgner PL, Gadek TR, Holm M et al. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413-17.
45. Boussif O, Lezoualc'h F, Zanta MA et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in.vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297-301.
46. Li S, Huang L. In.vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther 1997; 4: 891-900.
47. Kogure K, Moriguchi R, Sasaki K, Ueno M, Futaki S, Harashima H. Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J Control Release 2004; 98: 317-23.
48. Yang JP, Huang L. Overcoming the inhibitory effect of serum on lipofection by increasing the charge ratio of cationic liposome to DNA. Gene Ther 1997; 4: 950-60.
49. Opanasopit P, Nishikawa M, Hashida M. Factors affecting drug and gene delivery: Effects of interaction with blood components. Crit Rev Ther Drug Carrier Syst 2002; 19: 191-233.
50. Nishikawa M, Takemura S, Takakura Y, Hashida M. Targeted delivery of plasmid DNA to hepatocytes in.vivo: Optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(l-lysine) complexes by controlling their physicochemical properties. J Pharmacol Exp Ther 1998; 287: 408-15.
51. Nishikawa M, Yamauchi M, Morimoto K, Ishida E, Takakura Y, Hashida M. Hepatocyte-targeted in.vivo gene expression by intravenous injection of plasmid DNA complexed with synthetic multi-functional gene delivery system. Gene Ther 2000; 7: 548-55.
52. Kawakami S, Fumoto S, Nishikawa M, Yamashita F, Hashida M. In.vivo gene delivery to the liver using novel galactosylated cationic liposomes. Pharm Res 2000; 17: 306-13.
53. Kawakami S, Sato A, Nishikawa M, Yamashita F, Hashida M. Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes. Gene Ther 2000; 7: 292-9.
54. Morimoto K, Nishikawa M, Kawakami S et al. Molecular weight-dependent gene transfection activity of unmodified and galactosylated polyethyleneimine on hepatoma cells and mouse liver. Mol Ther 2003; 7: 254-61.
55. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000; 65: 271-84.
56. Kobayashi N, Kuramoto T, Yamaoka K, Hashida M, Takakura Y. Hepatic uptake and gene expression mechanisms following intravenous administration of plasmid DNA by conventional and hydrodynamics-based procedures. J Pharmacol Exp Ther 2001; 297: 853-60.
57. Hisazumi J, Kobayashi N, Nishikawa M, Takakura Y. Significant role of liver sinusoidal endothelial cells in hepatic uptake and degradation of naked plasmid DNA after intravenous injection. Pharm Res 2004; 21: 1223-8.
58. Li S, Tseng WC, Stolz DB, Wu SP, Watkins SC, Huang L. Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: Implications for intravenous lipofection. Gene Ther 1999; 6: 585-94.
59. Sakurai F, Nishioka T, Saito H et al. Interaction between DNA-cationic liposome complexes and erythrocytes is an important factor in systemic gene transfer via the intravenous route in mice: The role of the neutral helper lipid. Gene Ther 2001; 8: 677-86.
60. Mahato RI, Kawabata K, Nomura T, Takakura Y, Hashida M. Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes. J Pharm Sci 1995; 84: 1267-71.
61. Liu Y, Mounkes LC, Liggitt HD et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 1997; 15: 167-73.
62. Kircheis R, Wightman L, Kursa M, Ostermann E, Wagner E. Tumor-targeted gene delivery: An attractive strategy to use highly active effector molecules in cancer treatment. Gene Ther 2002; 9: 731-5.
63. Ward CM, Pechar M, Oupicky D, Ulbrich K, Seymour LW. Modification of pLL/ DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targeting in.vitro and prolonged plasma circulation in.vivo. J Gene Med 2002; 4: 536-47.
64. Li S, Tan Y, Viroonchatapan E, Pitt BR, Huang L. Targeted gene delivery to pulmonary endothelium by anti-PECAM antibody. Am J Physiol 2000; 278: L504-11.
65. Kursa M, Walker GF, Roessler V et al. Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer. Bioconjug Chem 2003; 14: 222-31.
66. Moffatt S, Wiehle S, Cristiano RJ. Tumor-specific gene delivery mediated by a novel peptide-polyethylenimine-DNA polyplex targeting aminopeptidase N/CD13. Hum Gene Ther 2005; 16: 57-67.
67. Hatakeyama H, Akita H, Kogure K et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther 2007; 14: 68-77.
68. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in.vivo. Gene Ther 1999; 6: 508-14.
69. Basser RL, Rasko JE, Clarke K et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348: 1279-81.
70. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 2000; 97: 8548-53.
71. Pepinsky RB, LePage DJ, Gill A et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with preserved in.vitro bioactivity. J Pharmacol Exp Ther 2001; 297: 1059-66.
72. Nishikawa M, Tamada A, Kumai H, Yamashita F, Hashida M. Inhibition of experimental pulmonary metastasis by controlling biodistribution of catalase in mice. Int J Cancer 2002; 99: 474-9.
73. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Structural and biological characterization of pegylated recombinant interferon α-2b and its therapeutic implications. Adv Drug Deliv Rev 2002; 54: 547-70.
74. Hyoudou K, Nishikawa M, Umeyama Y, Kobayashi Y, Yamashita F, Hashida M. Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: Quantitative analysis with firefly luciferase-expressing melanoma cells. Clin Cancer Res 2004; 10: 7685-91.
75. Hyoudou K, Nishikawa M, Kobayashi Y, Umeyama Y, Yamashita F, Hashida M. PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Free Radic Biol Med 2006; 41: 1449-58.
76. Ochiya T, Takahama Y, Nagahara S et al. New delivery system for plasmid DNA in.vivo using atelocollagen as a carrier material: The Minipellet. Nat Med 1999; 5: 707-10.
77. Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J. A new DNA vehicle for nonviral gene delivery: Supercoiled minicircle. Gene Ther 1997; 4: 1341-9.
78. Saeki Y, Wataya-Kaneda M, Tanaka K, Kaneda Y. Sustained transgene expression in.vitro and in.vivo using an Epstein-Barr virus replicon vector system combined with HVJ liposomes. Gene Ther 1998; 5: 1031-7.
79. Yew NS, Przybylska M, Ziegler RJ, Liu D, Cheng SH. High and sustained transgene expression in.vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol Ther 2001; 4: 75-82.
80. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in.vivo. Mol Ther 2003; 8: 495-500.